Amgen news
The WiseView Research desk's stories that name Amgen, the latest headlines about it, and the trades members of Congress and company insiders have disclosed. The AMGN page →
- HeadlineAmgen Q3 Earnings: Will Strong Drug Sales Offset Headwinds?
- HeadlineAmgen (AMGN) Reports Next Week: Wall Street Expects Earnings Growth
- HeadlineAmgen vs. Novo Nordisk: Which Healthcare Giant's Stock Is a Better Buy in 2026?
- HeadlineAmgen: A Biotech Bargain Heading Into Q3 Earnings
- HeadlineAMGEN APPOINTS DAVID W. GIBBS TO BOARD OF DIRECTORS
- HeadlineAmgen vs. Gilead Sciences: Which Biotech Dividend Stock Is the Better Buy?
- HeadlineAmgen Inc. (AMGN) Presents at 2026 European Society for Medical Oncology (ESMO) Annual Congress Transcript
- HeadlineAmgen's IMDELLTRA Cuts Death Risk 58% in Small-Cell Lung Cancer Study
- HeadlineAmgen says drug combo cuts risk of death by 58% in patients with aggressive lung cancer
- HeadlineHere's Why Amgen (AMGN) Fell More Than Broader Market
- HeadlineAmgen (AMGN) Gains As Market Dips: What You Should Know
- HeadlineAmgen vs. Eli Lilly: Does the GLP-1 Mania Make LLY Stock a Better Buy in 2026?
- HeadlineAmgen vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?
- HeadlineAMGEN TO PRESENT AT THE EUROPEAN SOCIETY OF MEDICAL ONCOLOGY CONGRESS 2026
- HeadlineEli Lilly Rises 4% While Foundayo Nears European Approval; Amgen and Novo Nordisk Edge Higher
- HeadlineHere's Why Amgen (AMGN) is a Strong Growth Stock
- HeadlineTEZSPIRE® DELIVERED HISTOLOGIC REMISSION AND SYMPTOM IMPROVEMENT IN EOSINOPHILIC ESOPHAGITIS
- HeadlineAmgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know
- HeadlineAmgen (AMGN) Exceeds Market Returns: Some Facts to Consider
- HeadlineAMGN vs. MRK: Which Pharma Giant's Dividend Actually Has Room to Grow
- HeadlineHere's Why Amgen (AMGN) is a Strong Momentum Stock
- HeadlineAmgen (AMGN) Laps the Stock Market: Here's Why
- CongressRo Khanna bought $1,001 - $15,000 of AMGN
- HeadlineAmgen (AMGN) Advances While Market Declines: Some Information for Investors
- CongressDavid Taylor bought $1,001 - $15,000 of AMGN
- HeadlineAmgen (AMGN) Stock Dips While Market Gains: Key Facts
- HeadlineLilly vs. Novo: Inside the Milan EASD Showdown and the ETFs Poised to Win
- HeadlineWhy Amgen's 6% Dividend Raise Masks a Tougher Road Ahead
- CongressDavid Taylor sold $1,001 - $15,000 of AMGN
- CongressSheldon Whitehouse sold $1,001 - $15,000 of AMGN
- CongressTommy Tuberville sold $15,001 - $50,000 of AMGN
- CongressRo Khanna bought $1,001 - $15,000 of AMGN
- CongressDavid Taylor bought $1,001 - $15,000 of AMGN
- CongressMark Warner sold $1,001 - $15,000 of AMGN
Headlines link to their publishers. Members of Congress disclose ranges, not exact amounts, and may file weeks after the trade; insider filings are open-market purchases and sales from SEC Form 4. For information only, not investment advice.